ABSTRACT
Background To evaluate the utility of polygenic risk scores (PRS) in identifying high-risk individuals, different publicly available PRS for breast (n=65), prostate (n=26), colorectal (n=12) and lung cancers (n=7) were examined in a prospective study of 21,694 Chinese adults.
Methods We constructed PRS using weights curated in the online PGS Catalog. PRS performance was evaluated by distribution, discrimination, predictive ability, and calibration. Hazard ratios (HR) and corresponding confidence intervals [CI] of the common cancers after 20 years of follow-up were estimated using Cox proportional hazard models for different levels of PRS.
Results A total of 495 breast, 308 prostate, 332 female-colorectal, 409 male-colorectal, 181 female-lung and 381 male-lung incident cancers were identified. The area under receiver operating characteristic curve for the best performing site-specific PRS were 0.61 (PGS000004, breast), 0.66 (PGS00586, prostate), 0.58 (PGS000148, female-colorectal), 0.60 (PGS000734, male-colorectal) and 0.55 (PGS000740, female-lung), and 0.55 (PGS000392, male-lung), respectively. Compared to the middle quintile, individuals in the highest PRS quintile were 67% more likely to develop cancers of the breast, prostate, and colorectal. For lung cancer, the lowest PRS quintile was associated with 31-45% decreased risk compared to the middle quintile. In contrast, the hazard ratios observed for quintiles 4 (female-lung: 0.91 [0.58-1.44]; male-lung: 1.01 [0.74-1.38]) and 5 (female-lung: 1.00 [0.64-1.56]; male-lung: 1.07 [0.79-1.45]) were not significantly different from that for the middle quintile.
Conclusions Site-specific PRSs can stratify the risk of developing breast, prostate, and colorectal cancers in this East Asian population. Appropriate correction factors may be required to improve calibration.
Funding This work is supported by the National Research Foundation Singapore (NRF-NRFF2017-02), PRECISION Health Research, Singapore (PRECISE) and the Agency for Science, Technology and Research (A*STAR). WP Koh was supported by National Medical Research Council, Singapore (NMRC/CSA/0055/2013). CC Khor was supported by National Research Foundation Singapore (NRF-NRFI2018-01). Rajkumar Dorajoo received a grant from the Agency for Science, Technology and Research Career Development Award (A*STAR CDA - 202D8090), and from Ministry of Health Healthy Longevity Catalyst Award (HLCA20Jan-0022).
The Singapore Chinese Health Study was supported by grants from the National Medical Research Council, Singapore (NMRC/CIRG/1456/2016) and the U.S. National Institutes of Health [NIH] (R01 CA144034 and UM1 CA182876).
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work is supported by the National Research Foundation Singapore (NRF-NRFF2017-02), PRECISION Health Research, Singapore (PRECISE) and the Agency for Science, Technology and Research (A*STAR). WP Koh was supported by National Medical Research Council, Singapore (NMRC/CSA/0055/2013, respectively). CC Khor was supported by National Research Foundation Singapore (NRF-NRFI2018-01). The Singapore Chinese Health Study was supported by the National Medical Research Council, Singapore (NMRC/CIRG/1456/2016) and National Institutes of Health, USA (NCI RO1 CA55069, UM1 CA182876, R35 CA53890, R01 CA80205, and R01 CA144034).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Institutional Review Boards of the National University of Singapore, University of Minnesota and the Agency for Science, Technology and Research (A*STAR). Written, informed consent was obtained from all study participants.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
hopj{at}gis.a-star.edu.sg
iain.tan.b.h{at}singhealth.com.sg
dawn.chong.q.q{at}singhealth.com.sg
khorcc{at}gis.a-star.edu.sg
yuanj{at}upmc.edu
kohwp{at}nus.edu.sg
dorajoor{at}gis.a-star.edu.sg
lijm1{at}gis.a-star.edu.sg
Data Availability
All data produced in the present study are available upon reasonable request to the authors
